Uniqure NV (NASDAQ:QURE) has earned a consensus recommendation of “Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $75.38.

Several equities analysts recently commented on QURE shares. Guggenheim started coverage on Uniqure in a research report on Monday, December 17th. They set a “buy” rating and a $35.00 target price for the company. B. Riley began coverage on Uniqure in a research report on Monday, December 31st. They issued a “buy” rating and a $72.00 price objective for the company. Zacks Investment Research downgraded Uniqure from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. HC Wainwright set a $60.00 price objective on Uniqure and gave the company a “buy” rating in a research report on Monday, January 14th. Finally, BidaskClub upgraded Uniqure from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 31st.

In other news, Director David Schaffer sold 7,500 shares of Uniqure stock in a transaction on Thursday, January 17th. The stock was sold at an average price of $30.71, for a total value of $230,325.00. Following the completion of the sale, the director now directly owns 43,701 shares of the company’s stock, valued at approximately $1,342,057.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Christian Klemt sold 1,479 shares of Uniqure stock in a transaction on Monday, January 28th. The shares were sold at an average price of $31.29, for a total value of $46,277.91. Following the completion of the sale, the chief accounting officer now directly owns 56,085 shares of the company’s stock, valued at $1,754,899.65. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,651 shares of company stock valued at $5,963,013. Corporate insiders own 1.56% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc grew its stake in shares of Uniqure by 264.2% during the fourth quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 700 shares during the period. Exane Derivatives acquired a new position in Uniqure in the fourth quarter valued at about $41,000. Financial Gravity Companies Inc. acquired a new position in Uniqure in the fourth quarter valued at about $310,000. Advisor Group Inc. grew its stake in Uniqure by 5.3% in the fourth quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 502 shares during the period. Finally, HRT Financial LLC acquired a new position in Uniqure in the fourth quarter valued at about $289,000. 60.52% of the stock is owned by institutional investors.

Shares of Uniqure stock traded down $0.42 during midday trading on Thursday, hitting $57.78. 171,913 shares of the company were exchanged, compared to its average volume of 527,516. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.85 and a quick ratio of 11.85. The company has a market capitalization of $2.19 billion, a PE ratio of -24.69 and a beta of 1.08. Uniqure has a 52 week low of $21.98 and a 52 week high of $69.60.

Uniqure (NASDAQ:QURE) last posted its earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.08. Uniqure had a negative return on equity of 47.73% and a negative net margin of 738.25%. Equities analysts anticipate that Uniqure will post -3.01 earnings per share for the current fiscal year.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Read More: Why Invest in Dividend Achievers?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.